2025-10-15, Wed.

Top Stories       Business       Culture & Life       Science & Technology       World

Lecture

Notification

 

NEWS > Science & Technology


Ferring Japan Announces PMDA Acceptance of NDA Filing for Nadofaragene Firadenovec

Nadofaragene firadenovec is the first and only non-replicating gene therapy administered intravesically, and it is already approved and launched in the US.
Date: 2025-09-26

SAINT PREX, SWITZERLAND -- Ferring Pharmaceuticals Co., Ltd. announced that the PMDA has accepted the NDA for nadofaragene firadenovec for review, following submission on August 27th, 2025. This non-replicating gene therapy, administered intravesically, offers patients with NMIBC a bladder-sparing treatment option. Nadofaragene firadenovec’s quarterly dosing eliminates the burden of frequent treatments, while delivering a non-chemotherapy mechanism of action through interferon gene therapy. The NDA acceptance further highlights Ferring’s ongoing commitment to establish the new standard of care for high-risk BCG-unresponsive NMIBC.

Professor Keiji Inoue, M.D., Ph.D., Department of Urology, Kochi Medical School, stated: “Nadofaragene firadenovec represents an option for those who failed NMIBC treatment. As the first choice after BCG failure, this bladder sparing gene therapy offers patients a non-chemotherapy option that transforms their own bladder cells into interferon-producing factories. The 75% complete response rate achieved with convenient quarterly dosing provides hope for patients who previously faced limited treatment options.”

The NDA for nadofaragene firadenovec is based on results from a Phase 3 trial conducted in Japan.[1] The primary outcome of a complete response (CR) rate of 75% at 3 months, following a single dose in 20 high-risk Japanese patients with carcinoma in situ (CIS), with or without concomitant high-grade Ta or T1 papillary lesions, was presented at the 112th Annual Meeting of the Japanese Urological Association (JUA, April 17-19, 2025, Fukuoka). All treatment-related adverse events were limited to Grade 1 (84.2%) or Grade 2 (15.8%), with zero Grade 3, 4, or 5 adverse events reported - confirming the therapy’s favourable safety and tolerability profile.[1]

These results are consistent with independent US real-world data presented by the Mayo Clinic, which demonstrated 79% complete response rate.[2] The results from the Mayo Clinic were achieved following a single quarterly dosing, representing clinical and convenience advantages over existing therapies, without requiring re-induction protocols.[2] Patients who achieved complete response continued quarterly maintenance dosing.

Joern Jakobsen, M.D., Ph.D., Vice President and Head of Global Research and Medical for Uro-Oncology and Urology, Ferring Pharmaceuticals stated “Traditionally, when BCG therapy proved insufficient, patients had no choice but to undergo highly invasive treatments such as radical cystectomy or risk cancer progression. Nadofaragene firadenovec is expected to offer a new bladder-sparing treatment option. At Ferring, we are committed to addressing the unmet needs in bladder cancer treatment by providing urologists with critical insights that enable effective, personalised, and groundbreaking therapies.”

“Our ambition is to establish nadofaragene firadenovec as the new standard of care and the backbone therapy for NMIBC treatment,” said Bipin Dalmia, Global Head, Uro-Oncology & Urology Franchise. “High-risk NMIBC patients who no longer respond to BCG have endured decades of little progress and currently face bladder removal as their primary option. This PMDA acceptance validates our strategic commitment to bring this treatment to Japanese patients.”



 to the Top List of News

SES delivered unprecedented MEO satellite connectivity for French Navy¡¯s Clemenceau 25 mission
KBS Partners with Rimini Street to Accelerate its AI Vision
LSEG Launches Digital Markets Infrastructure Platform for Private Funds, and Facilitates First Transaction
IFF¡¯s Designed Enzymatic Biomaterials¢â Platform Sees First Large-Scale Use in Home Care Applications
PubNub Powers Historic FIFA Club World Cup 2025¢â Broadcast with DAZN, Creating the World¡¯s Largest Virtual Fan Experience
Swedish Commercial Vehicle Giant Picks HCLTech for AI Digital Services, Expands & Renews Strategic Tech Partnership
Home Swing Home: Redefining My Desk Décor With LG¡¯s Smart Monitor Swing

 

Rigaku Launches Sales of the XHEMIS TX-3000, a TXRF Analytical System ...
Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive...
Omdia: LTPO to Surpass LTPS as Dominant Technology for Flexible Smartp...
LG Launches 4K Surgical Monitor With Intelligent Features To Optimize ...
WeFi Technology Group - Opening Finance Access To Technology Distribut...
Power Integrations Rolls Out Reference Design Kit for Solar Race Cars ...
SES and K2 Space to Accelerate Development of Next-Generation MEO Netw...
MEDIPEAU Showcases its Film-Type Wound Dressing Cream at 51st Annual F...
The New Belkin UltraCharge Collection Brings Fast, Stylish Power at 25...
Smart Scent Platform Deepscent AI Competes in Four Categories at CES 2...

 

 

60, Gamasanro 27gil, Guro-gu, Seoul, Korea, e-mail: news@newsji.com

Copyright, NEWSJI NETWORK.